255 related articles for article (PubMed ID: 16333707)
41. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers.
Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A;
Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918
[TBL] [Abstract][Full Text] [Related]
42. Newer radiological techniques in the diagnosis of gastrointestinal cancer.
Dodd GD; Goldstein HM
Clin Gastroenterol; 1976 Sep; 5(3):597-624. PubMed ID: 1022376
[No Abstract] [Full Text] [Related]
43. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
45. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Takita J; Kimura H; Faried A; Sohda M; Fukai Y; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Kuwano H; Oriuchi N; Endo K
Cancer; 2005 Jan; 103(1):148-56. PubMed ID: 15558794
[TBL] [Abstract][Full Text] [Related]
46. Impact of 68 Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors.
Kosmala A; Serfling SE; Schlötelburg W; Lindner T; Michalski K; Schirbel A; Higuchi T; Hartrampf PE; Buck AK; Weich A; Werner RA
Clin Nucl Med; 2023 Jan; 48(1):35-42. PubMed ID: 36354691
[TBL] [Abstract][Full Text] [Related]
47. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
48. PET/CT: will it change the way that we use CT in cancer imaging?
Hicks RJ; Ware RE; Lau EW
Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
[TBL] [Abstract][Full Text] [Related]
49. PET/MRI of the hepatobiliary system: Review of techniques and applications.
Guniganti P; Kierans AS
Clin Imaging; 2021 Mar; 71():160-169. PubMed ID: 33285404
[TBL] [Abstract][Full Text] [Related]
50. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
51. False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer.
Paudel N; Kunz PL; Poultsides GA; Koong AC; Chang DT
Pract Radiat Oncol; 2014; 4(6):368-71. PubMed ID: 25407856
[No Abstract] [Full Text] [Related]
52. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
53. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update.
Kitajima K; Nakajo M; Kaida H; Minamimoto R; Hirata K; Tsurusaki M; Doi H; Ueno Y; Sofue K; Tamaki Y; Yamakado K
Nagoya J Med Sci; 2017 Nov; 79(4):527-543. PubMed ID: 29238109
[TBL] [Abstract][Full Text] [Related]
54. [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications].
Pasquali C; Sperti C; Lunardi C; Scappin S; Chierichetti F; Liessi G; Pedrazzoli S
Suppl Tumori; 2005; 4(3):S68-71. PubMed ID: 16437910
[TBL] [Abstract][Full Text] [Related]
55. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
[TBL] [Abstract][Full Text] [Related]
56. Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
Schillaci O
J Nucl Med; 2014 Nov; 55(11):1757-8. PubMed ID: 25342386
[No Abstract] [Full Text] [Related]
57. PET/CT in oncology--a major advance.
Wechalekar K; Sharma B; Cook G
Clin Radiol; 2005 Nov; 60(11):1143-55. PubMed ID: 16223611
[TBL] [Abstract][Full Text] [Related]
58. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers.
Jadvar H
Semin Nucl Med; 2012 Jul; 42(4):247-54. PubMed ID: 22681673
[TBL] [Abstract][Full Text] [Related]
59. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary.
Freudenberg LS; Fischer M; Antoch G; Jentzen W; Gutzeit A; Rosenbaum SJ; Bockisch A; Egelhof T
Med Princ Pract; 2005; 14(3):155-60. PubMed ID: 15863988
[TBL] [Abstract][Full Text] [Related]
60. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
